202 related articles for article (PubMed ID: 17435860)
21. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.
Vilar L; Vilar CF; Lyra R; Freitas MDC
Neuroendocrinology; 2019; 109(1):7-19. PubMed ID: 30889571
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.
Vilar L; Freitas MC; Naves LA; Casulari LA; Azevedo M; Montenegro R; Barros AI; Faria M; Nascimento GC; Lima JG; Nóbrega LH; Cruz TP; Mota A; Ramos A; Violante A; Lamounier Filho A; Gadelha MR; Czepielewski MA; Glezer A; Bronstein MD
J Endocrinol Invest; 2008 May; 31(5):436-44. PubMed ID: 18560262
[TBL] [Abstract][Full Text] [Related]
23. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
[TBL] [Abstract][Full Text] [Related]
24. Comparison of PEG precipitation and ultrafiltration treatment for serum macroprolactin in Chinese patients with hyperprolactinemia.
Ke X; Wang L; Duan L; Yang H; Yin J; Qiu L; Pan H; Gong F; Zhu H
Clin Chim Acta; 2023 Apr; 544():117358. PubMed ID: 37086942
[TBL] [Abstract][Full Text] [Related]
25. Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.
Amadori P; Dilberis C; Marcolla A; Pinamonti M; Menapace P; Dal Bosco F
J Endocrinol Invest; 2003 Feb; 26(2):148-56. PubMed ID: 12739743
[TBL] [Abstract][Full Text] [Related]
26. Serum prolactin and macroprolactin levels in diabetic nephropathy.
Sari F; Sari R; Ozdem S; Sarikaya M; Cetinkaya R
Clin Nephrol; 2012 Jul; 78(1):33-9. PubMed ID: 22732335
[TBL] [Abstract][Full Text] [Related]
27. A New Method of Using Polyethylene Glycol (PEG) Precipitation of Macroprolactin to Detect Genuine Hyperprolactinemia.
Chen Y; Wang H; Yang W; Jin W; Yu W; Wang W; Zhang K; Song G
J Clin Lab Anal; 2016 Nov; 30(6):1169-1174. PubMed ID: 27219457
[TBL] [Abstract][Full Text] [Related]
28. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
Lu CC; Hsieh CJ
Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536
[TBL] [Abstract][Full Text] [Related]
29. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia.
Can M; Guven B; Atmaca H; Acıkgoz S; Mungan G
Kaohsiung J Med Sci; 2011 May; 27(5):173-6. PubMed ID: 21527183
[TBL] [Abstract][Full Text] [Related]
30. Macroprolactinemia in childhood and adolescence: a cause of hyperprolactinemia.
Tütüncüler F; Darendeliler F; Aygün M; Hekim N
Turk J Pediatr; 2006; 48(2):143-7. PubMed ID: 16848115
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.
Tamer G; Telci A; Mert M; Uzum AK; Aral F; Tanakol R; Yarman S; Boztepe H; Colak N; Alagöl F
Endocrine; 2012 Feb; 41(1):138-43. PubMed ID: 21959531
[TBL] [Abstract][Full Text] [Related]
32. The importance of macroprolactinemia in the differential diagnosis of hyperprolactinemic patients.
Bağdatoğlu C; Bağdatoğlu OT; Muslu N; Köseoğlu A; Dağtekin A; Polat G; Dolgun H; Karataş MA
Turk Neurosurg; 2008 Jul; 18(3):223-7. PubMed ID: 18814107
[TBL] [Abstract][Full Text] [Related]
33. [Macroprolactinemia identification in patients with hyperprolactinemia].
Sandoval C; González B; Cheng S; Esquenazi Y; Mercado M
Ginecol Obstet Mex; 2007 Aug; 75(8):459-64. PubMed ID: 18293675
[TBL] [Abstract][Full Text] [Related]
34. Importance of screening for macroprolactin in all hyperprolactinaemic sera.
Jamaluddin FA; Sthaneshwar P; Hussein Z; Othman N; Chan SP
Malays J Pathol; 2013 Jun; 35(1):59-63. PubMed ID: 23817395
[TBL] [Abstract][Full Text] [Related]
35. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.
Leslie H; Courtney CH; Bell PM; Hadden DR; McCance DR; Ellis PK; Sheridan B; Atkinson AB
J Clin Endocrinol Metab; 2001 Jun; 86(6):2743-6. PubMed ID: 11397880
[TBL] [Abstract][Full Text] [Related]
36. Optimization of a Screening Method for Macroprolactinemia.
Yang W; Guo Z; Zhou Y; Du J; Liu H; Jia J; Shen Y; Chen Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122723. PubMed ID: 33989987
[TBL] [Abstract][Full Text] [Related]
37. Macroprolactinemia Detection by Magnetically Assisted Polyethylene Glycol Precipitation: Potential for Automation.
Smith T; Stern E; Tan E; Vacic A; Fahie-Wilson M
J Appl Lab Med; 2020 May; 5(3):494-505. PubMed ID: 32445359
[TBL] [Abstract][Full Text] [Related]
38. Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.
Espinós JJ; Vanrell C; Gich I; Urgell E; Calaf J
Gynecol Endocrinol; 2017 Feb; 33(2):148-151. PubMed ID: 27841032
[TBL] [Abstract][Full Text] [Related]
39. Macroprolactinemia: a mini-review and update on clinical practice.
Koniares K; Benadiva C; Engmann L; Nulsen J; Grow D
F S Rep; 2023 Sep; 4(3):245-250. PubMed ID: 37719092
[TBL] [Abstract][Full Text] [Related]
40. Macroprolactinemia and Empty Sella Syndrome.
Taieb A; Maha KN; El Abed YH; Beizig AM; Chadli MC; Ach K
Pan Afr Med J; 2017; 27():278. PubMed ID: 29187947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
